Neurotech Partners with RH Pharma to Develop Pharmaceutical-Grade Cannabinoid Therapy

Neurotech International Limited (ASX: NTI), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, has signed a binding Development Agreement with RH Pharma, a subsidiary of European Cannabis Company (ECC). This partnership aims to develop a pharmaceutical-grade broad-spectrum cannabinoid drug for neurodevelopmental disorders using RH Pharma’s proprietary CO2 extraction technology. The collaboration supports Neurotech’s proprietary formulations, which have shown significant improvements in conditions like autism, Rett Syndrome, and PANDAS/PANS. Under the agreement, RH Pharma will utilize GMP-compliant processes to create a consistent, strain-agnostic cannabinoid drug meeting global regulatory standards. Neurotech will pay an initial €25,000, with additional services available over the 12-month term. The agreement strengthens Neurotech’s position in the pharmaceutical cannabis market, ensuring scalability and quality compliance. CEO Dr. Anthony Filippis emphasized the importance of this partnership in expanding global reach and supporting regulatory approvals for NTI64. ECC’s General Manager, Rebeka Levy, highlighted the shared vision for innovation and international expansion.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com